Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Here are details of Agomab‘s latest funding round :
🚀 Launch
2017
🏭 Industry
Biotechnology
🧠Management
Tim Knotnerus (CEO), Philippe Wiesel (Chief Medical Officer), Andrea Sáez (Chief Development Officer), Tolga Hassan (CFO), Paul van der Horst (Chief Business Officer)
💸 Funding & Investors
| INVESTMENT (October 2023) | €94.9 million (Series C) |
| INVESTORS (October 2023) | led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors. |
🎯 Funding purpose
Support its Phase 2a clinical trial, STENOVA, which will evaluate the effectiveness of the lead candidate AGMB-129. The drug is a gut-restricted small molecule inhibitor of ALK5 and will be tested on patients with Fibrostenosing Crohn’s Disease (FSCD).
🌐 Country HQ
Belgium (Ghent)